Recently, immune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1 inhibitors, have emerged as a significant therapeutic approach for advanced and metastatic ccRCC [4]. Here, PDCD1 is linked to nonpapillary renal cell carcinoma.